ClinicalTrials.gg
CompletedNCT07707141Updated Aug 3, 2026

Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis

A Phase 2 interventional study of HPP737 6mg and placebo and HPP737 10mg and placebo in Psoriasis, sponsored by Newsoara Biopharma Co., Ltd.. Completed at 8 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Newsoara Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 10 months ago, and no results have been posted to the registry.
  • Registered 5 years 4 months after the study started (first participant enrolled Mar 2021, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
112th of 182
123 · median 171
Started
2021
with 19 others
Phase 2
42 of 206
11 open now
Registered
196th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 112th largest by enrollment of the 182 interventional ones that give a count, is one of 20 that started in 2021, is one of 42 in phase 2, and was the 196th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are:

Does drug HPP737 improve psoriasis severity compared to placebo, as measured by the proportion of patients achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) at Day 85? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to a placebo (a look-alike substance that contains no drug) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis.

Participants will:

Take drug HPP737 or a placebo orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools (PASI, Physician's Global Assessment (PGA), and Body Surface Area ( BSA)) This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial. Eligible participants are adults aged 18 to 70 years with chronic plaque psoriasis for at least 6 months and moderate-to-severe disease at screening.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Moderate to Severe Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must voluntarily sign before any study-related procedures are initiated, be able to communicate effectively with the investigator, and be able to understand and comply with the requirements of this trial.
  • Age at the time of signing the informed consent: 18 years ≤ age ≤ 70 years, regardless of gender.
  • A documented history of chronic plaque psoriasis for ≥ 6 months.
  • Moderate-to-severe plaque psoriasis meeting all of the following criteria: a) PASI (Psoriasis Area and Severity Index) score ≥12; and b) PGA (Physician's Global Assessment) score ≥3; and c) BSA (Body Surface Area) score ≥10%.
  • Subjects are considered suitable for systemic therapy and/or phototherapy and/or photochemotherapy for psoriasis by the investigator.
  • (BMI): 18 kg/m2 ≤ BMI ≤ 35 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • At screening, diagnosis of psoriasis is not chronic plaque-type psoriasis (e.g., pustular psoriasis, erythrodermic psoriasis, or guttate psoriasis).
  • Patients with drug-induced psoriasis (triggered by medications such as β-blockers [beta-receptor blocking agents], calcium channel inhibitors [calcium channel blockers], or lithium) are included.
  • Had a serious or systemic infection within 8 weeks before baseline that required intravenous anti-infective treatment or hospitalization due to infection.
  • Presence of other dermatological conditions considered by the investigator to interfere with psoriasis assessment (e.g., skin bacterial, fungal, or viral infections; seborrheic dermatitis).
  • History of inflammatory bowel disease or concurrent other active diseases.
  • History or symptoms of in any organ system within 5 years prior to screening, whether or not treated, and regardless of evidence of recurrence or .
  • Subjects with a history of depression and/or who exhibit suicidal ideation or any suicidal behavior during the screening period and at baseline as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS, Posner K et al, 2011) will be excluded. If a subject answers "Yes" to any item on the C-SSRS questionnaire, or if the investigator clinically determines the subject to be at risk, the subject will be excluded from the study.
  • Donation of blood or blood loss ≥400 mL within 8 weeks prior to baseline and/or planned blood donation during the study period.
  • History of moderate-to-severe heart failure ( [NYHA] functional classification ≥Class 3), cardiovascular or cerebrovascular event, or other severe adverse events within 3 months prior to screening, and the investigator determines that such subjects are not suitable for participation in this clinical study.
  • Any clinical condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this clinical trial.
  • Known allergy to any component or of the product, or to other biological agents.
  • Concomitant use of any of the following psoriasis treatments/medications: a) Tumor necrosis factor alpha (TNF-α) antagonist: ① Prior use of a single TNF-α antagonist (for example: use of adalimumab or infliximab within 60 days prior to baseline; use of golimumab within 90 days prior to baseline; use of etanercept within 28 days prior to baseline); ② or prior use of two or more TNF-α antagonists before screening. b) History of the use of other biologic agents prior to screening: including but not limited to anti-interleukin 17 (IL-17) agents, anti-IL-17 receptor agents, anti-IL-12/IL-23 class of drugs; c) Phototherapy/photochemotherapy (including psoralen plus ultraviolet A [PUVA] therapy, ultraviolet B [UVB], or systemic therapies [e.g., methotrexate, cyclosporine, cyclophosphamide, etc.]) within 4 weeks prior to baseline; d) Within 2 weeks prior to baseline, subjects received topical treatment for psoriasis, such as medium to high-potency , vitamin D3 derivatives, or retinoids; however, the following topical treatments are permitted: low-potency corticosteroids (potency classes 6-7), non-medicated shampoos (i.e., those not containing corticosteroids, vitamin D3 derivatives, calcineurin inhibitors, etc.), and emollients without α- or β-hydroxy acids. Received traditional Chinese medicine (TCM) therapy for psoriasis within 2 weeks before baseline.
  • Use of oral or injectable glucocorticoids within 2 weeks before baseline.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    HPP737 6 mg

    Drug: HPP737 6mg and placebo

  • Experimental
    HPP737 10 mg

    Drug: HPP737 10mg and placebo

  • Experimental
    HPP737 20 mg

    Drug: HPP737 20mg

  • Placebo comparator
    HPP737 placebo

    Drug: HPP737 placebo

Interventions

  • DrugHPP737 6mg and placebo

    Specification: 1 mg/capsule, 5 mg/capsule; Dosage and administration: 4 capsules (including 1 mg HPP737 drug × 1 capsule, 5 mg HPP737 × 1 capsule, 2 placebo capsules), oral use, once daily for 85 consecutive days.

    Also known as: Prifemilast

  • DrugHPP737 10mg and placebo

    Specification: 1 mg/capsule, 5 mg/capsule; Dosage and administration: 4 capsules (including 5 mg HPP737 × 2 capsule, 2 placebo capsules), oral use, once daily for 85 consecutive days.

    Also known as: Prifemilast

  • DrugHPP737 20mg

    Specification: 1 mg/capsule, 5 mg/capsule; Dosage and administration: 4 capsules (including 5 mg HPP737 ×4 capsules), oral use, once daily for 85 consecutive days.

    Also known as: Prifemilast

  • DrugHPP737 placebo

    Specification: 1 mg/capsule, 5 mg/capsule; Dosage and administration: 4 capsules (including 4 placebo capsules), oral use, once daily for 85 consecutive days.

    Also known as: Prifemilast

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75 response) from baseline at Day 85.

    Time frame: 85 days

Secondary outcomes

  1. Proportion of subjects achieving a PASI 90 response at Day 85.

    Time frame: 85 days

  2. Incidence and severity of adverse events

    including evaluate abnormal findings in vital signs, physical examination, electrocardiogram (ECG) and clinical laboratory tests

    Time frame: 85 days

07

Study locations

8 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, China
  • Shandong Provincial Hospital for Skin Diseases, Shandong First Medical University
    Jinan, China
  • The First People's Hospital of Lianyungang
    Lianyungang, China
  • Hospital of Dermatology, Chinese Academy of Medical Sciences
    Nanjing, China
  • Hong Kong University Shenzhen Hospital
    Shenzhen, China
  • Wuxi No.2 People's Hospital
    Wuxi, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Dec 2021, 9 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 16, 2026
StartActual
Mar 3, 2021
Primary completionActual
Dec 20, 2021
CompletionActual
Dec 20, 2021
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07707141
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Mar 3, 2021
Primary completion
Dec 20, 2021
Completion
Dec 20, 2021
Last update
Aug 3, 2026

Study contacts

Heng Gu
principal investigator · Hospital of Dermatology, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion